



(12) Translation of
European patent specification

(11) NO/EP 3428170 B1

NORWAY

(19) NO
(51) Int Cl.
C07D 498/14 (2006.01)
A61K 31/5383 (2006.01)
A61P 31/16 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2021.05.10
(80)	Date of The European Patent Office Publication of the Granted Patent	2021.01.06
(86)	European Application Nr.	18189193.8
(86)	European Filing Date	2016.04.27
(87)	The European Application's Publication Date	2019.01.16
(30)	Priority	2015.04.28, JP, 2015090909 2015.12.03, JP, 2015236844
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
	Designated Extension States:	BA ; ME
	Designated Validation States:	MA ; MD
(73)	Proprietor	SHIONOGI & CO., LTD, 1-8, Doshomachi 3-chome, Chuo-kuOsaka-shiOsaka 541- 0045, Japan
(72)	Inventor	KAWAI, Makoto, c/o Shionogi & Co., Ltd.1-1 Futabacho 3-chomeToyonaka-shi, Osaka 561-0825, Japan TOMITA, Kenji, c/o Shionogi & Co., Ltd.1-8, Doshomachi 3-chomeChuo-kuOsaka- shi, Osaka 5410045, Japan AKIYAMA, Toshiyuki, c/o Shionogi & Co., Ltd.1-1 Futabacho 3-chomeToyonaka-shi, Osaka 561-0825, Japan OKANO, Azusa, c/o Shionogi & Co., Ltd.1-1 Futabacho 3-chomeToyonaka-shi, Osaka 561-0825, Japan MIYAGAWA, Masayoshi, c/o Shionogi & Co., Ltd.1-1 Futabacho 3-chomeToyonaka- shi, Osaka 561-0825, Japan

(74) Agent or Attorney TANDBERG INNOVATION AS, Postboks 1570 Vika, 0118 OSLO, Norge

(54) Title **ANTI-INFLUENZA POLYCYCLIC PYRIDONE DERIVATIVE AND PRODRUG THEREOF**


(56) References

Cited: EP-A1- 2 620 436


Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. En forbindelse som er representert ved den følgende formelen:



eller



eller det farmasøytisk akseptable saltet derav.

2. En farmasøytisk sammensetning som omfatter forbindelsen ifølge krav 1, eller det farmasøytisk akseptable saltet derav.

3. En farmasøytisk sammensetning ifølge krav 2, for bruk ved behandling eller forebygging av en influensavirusinfeksjon.

4. En forbindelse ifølge krav 1 eller det farmasøytisk akseptable saltet derav, for bruk ved behandling eller forebygging av sykdom som er forårsaket av et virus som har cap-avhengig endonuklease.